Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2009

View Archived Issues

Novel Hsp90 inhibitors under development at Merck KGaA for the treatment of cancer

Merck & Co. imparts novel HDAC inhibitors for treating cancer

Torrent claims novel Hsp70 inducers with potential for treating stroke

Novel deuterated oseltamivir analogues developed at Protia for influenza

Recent Dainippon Sumitomo patent reports new renin inhibitors with antihypertensive properties

Protia imparts novel deuterated tenofovir analogues with anti-HIV properties

NeoPharm submits application to FDA for phase II study of LE-DT in prostate cancer

Astex and Cancer Research U.K. sign CTA for AT-9283 in childhood cancer

Dainippon Sumitomo recaps Q3 developments

Novogen plans to focus activities on its oncology program

No serious adverse events seen with OBP-601 in phase I study

NeuroSearch discontinues ABT-894 program in diabetic neuropathic pain

Oasmia's phase III Paclical study generates physician interest in Europe

Octapharma commences phase II study of Octagam in Alzheimer's disease

Oral laquinimod granted FDA fast track designation for multiple sclerosis

Conditionally replicative adenovirus shows activity in phase I ovarian cancer trial

Roche signs nonexclusive license agreement with MDRNA for RNAi-based therapeutics

HIV-1 subtype A/E vaccine is safe but not highly immunogenic in healthy Thai subjects

Telik implements reorganization to focus on Telintra and leading preclinical candidates

CD4 T cells modified ex vivo by lentiviral vector traffic to lymphoid tissues in HIV patients

Antisense presents update on development

IDMC for phase III trial of motesanib recommends resumption of enrollment

Doctors can now predict Pegasys treatment success in hepatitis B patients

France approves named patient supply for Ark's Cerepro

Teijin and Takeda receive FDA approval for febuxostat for hyperuricemia in gout

ViroPharma discontinues maribavir phase III liver transplant study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...